Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SOT201 |
| Synonyms | |
| Therapy Description |
SOT201 comprises a monoclonal antibody against PDCD1 (PD-1) fused to an IL-15 mutein and the sushi domain from IL15RA, which activates IL-15 signaling, potentially resulting in expansion of T-lymphocytes and tumor growth inhibition (J Immunother Cancer 2023;11). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SOT201 | PD-L1/PD-1 antibody 133 | SOT201 comprises a monoclonal antibody against PDCD1 (PD-1) fused to an IL-15 mutein and the sushi domain from IL15RA, which activates IL-15 signaling, potentially resulting in expansion of T-lymphocytes and tumor growth inhibition (J Immunother Cancer 2023;11). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06163391 | Phase I | SOT201 | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer | Recruiting | USA | FRA | ESP | CZE | BEL | 0 |